GFI1 is required for RUNX1/ETO positive acute myeloid leukemia

• Anna E. Marneth,
• Lacramioara Botezatu,
• Judith M. Hönes,
• Jimmy C.L. Israël,
• Judith Schütte,
• Lothar Vassen,
• Robert F. Lams,
• Saskia M. Bergevoet,
• Laura Groothuis,
• Amit Mandoli,
• Joost H.A. Martens,
• Gerwin Huls,
• Joop H. Jansen,
• Ulrich Dührsen,
• Tobias Berg,
• Tarik Möröy,
• Christian Wichmann,
• Mia-Chia Lo,
• Dong-Er Zhang,
• Bert A. van der Reijden,
• Cyrus Khandanpour

Affiliations

Anna E. Marneth

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

Lacramioara Botezatu

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany

Judith M. Hönes

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany;Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University Duisburg-Essen, Germany

Jimmy C.L. Israël

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

Judith Schütte

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany

Lothar Vassen

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany

Robert F. Lams

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany

Saskia M. Bergevoet

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

Laura Groothuis

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

Amit Mandoli

Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, The Netherlands

Joost H.A. Martens

Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, The Netherlands

Gerwin Huls

Department of Hematology, University Medical Center Groningen, University of Groningen, The Netherlands

Joop H. Jansen

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

Ulrich Dührsen

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany

Tobias Berg

Department of Medicine II-Hematology/Oncology, Goethe University, Frankfurt/Main, Germany

Tarik Möröy

Institut de recherches cliniques de Montréal (IRCM), Hematopoiesis and Cancer Research Unit, and Université de Montréal, Canada

Christian Wichmann

Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilian University Hospital, Munich, Germany

Mia-Chia Lo

Department of Pathology & Division of Biological Sciences, University of California San Diego, La Jolla, USA

Dong-Er Zhang

Department of Pathology & Division of Biological Sciences, University of California San Diego, La Jolla, USA

Bert A. van der Reijden

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

Cyrus Khandanpour

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany;Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Germany